Compare KORE & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KORE | NRXS |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | 539 | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 78.9M |
| IPO Year | N/A | 2023 |
| Metric | KORE | NRXS |
|---|---|---|
| Price | $9.20 | $6.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $13.00 |
| AVG Volume (30 Days) | 17.9K | ★ 122.7K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $8.96 | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $2.00 | $2.20 |
| 52 Week High | $9.22 | $9.33 |
| Indicator | KORE | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 41.68 |
| Support Level | $4.10 | $6.24 |
| Resistance Level | $9.22 | $7.79 |
| Average True Range (ATR) | 0.02 | 0.43 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 71.43 | 30.15 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).